From the ∗Lübeck Institute of Experimental Dermatology, University of Lübeck, Germany
†Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
‡ Clalit Health Services, Tel Aviv
§Sial Research Center, Division of Community Health, Ben-Gurion University of the Negev, Be'er Sheva
∥Department of Behavioral Sciences, Ariel University
¶Shalvata Mental Health Center, Hod Hasharon
#Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel
∗∗Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
††Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Address reprint requests to Khalaf Kridin, MD, PhD, Lübeck Institute of Experimental Dermatology, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany. E-mail: [email protected].
A.D.C. served as an advisor, investigator, or speaker for AbbVie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa.
The other authors have no funding or conflicts of interest to declare.
O.W. and A.D.C. contributed equally.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.dermatitisjournal.com).
